Search Results for "days"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for days. Results 1571 to 1580 of 1846 total matches.

Miglitol for Type 2 Diabetes Mellitus

   
The Medical Letter on Drugs and Therapeutics • May 21, 1999  (Issue 1053)
for renal impairment because the drug acts locally. The average cost to the patient for 30 days’ treatment ...
Miglitol, an oral alpha-glucosidase inhibitor similar to acarbase, is now available for treatment of type 2 diabetes.
Med Lett Drugs Ther. 1999 May 21;41(1053):49-50 |  Show IntroductionHide Introduction

PC Spes

   
The Medical Letter on Drugs and Therapeutics • Feb 19, 2001  (Issue 1098)
contains a mixture of eight herbs weighing 320 mg. The label recommends three to six capsules per day ...
PC Spes, a dietary supplement sold for "prostate health", is being used increasingly to treat prostate cancer.
Med Lett Drugs Ther. 2001 Feb 19;43(1098):15-6 |  Show IntroductionHide Introduction

GlucoWatch Biographer: A Noninvasive Glucose Monitoring Device

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
. CLINICAL STUDIES — Comparative one- to five-day trials in patients requiring treatment with insulin found ...
An automatic, noninvasive, glucose-monitoring device (GlucoWatch Biographer) has been approved for marketing by the FDA. The manufacturer states that it is not meant to replace a regular blood glucose meter.
Med Lett Drugs Ther. 2001 May 14;43(1104):42 |  Show IntroductionHide Introduction

Initial Treatment of Parkinson's Disease:Wait Just a Minute

   
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001  (Issue 1108)
cost to the patient for 30 days’ treatment with the lowest recommended dosage of a dopamine agonist ...
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):59-60 |  Show IntroductionHide Introduction

Anakinra (Kineret) For Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 18, 2002  (Issue 1124)
subcutaneously every day, and appears to be only modestly effective. It can be used alone or with another DMARD ...
Anakinra (Kineret - Amgen), an interleuken-1 (IL-1) receptor antagonist, has been approved by the FDA for treatment of moderately to severly active rheumatoid arthritis in adults who have failed at least one disease-modifying anti-rheumatic drug(DMARD) such as methotrexate (Medical Letter 2000; 24:57).
Med Lett Drugs Ther. 2002 Feb 18;44(1124):18-9 |  Show IntroductionHide Introduction

Hemolysis From Ceftriaxone

   
The Medical Letter on Drugs and Therapeutics • Nov 25, 2002  (Issue 1144)
have occurred as soon as 5 minutes after the first infusion and as long as 34 days into a course of ceftriaxone ...
Immune-mediated hemolysis is a rare adverse effect of second- and third-generation cephalosporins, especially cefotetan (Cefotan) (PA Arndt et al, Transfusion 1999; 39:1239). A recent report serves as a reminder that life-threatening immune-mediated hemolysis rarely can follow administration of ceftriaxone (Rocephin), one of the most commonly used parenteral antibiotics in the US (A Citak et al, J Paediatr Child Health 2002; 38:209).
Med Lett Drugs Ther. 2002 Nov 25;44(1144):100-1 |  Show IntroductionHide Introduction

Ophthalmic Cyclosporine (Restasis) for Dry Eyes

   
The Medical Letter on Drugs and Therapeutics • May 26, 2003  (Issue 1157)
in Price Alert, May 15, 2003. If patients adhere to the labeling, they would need to use 2 vials per day ...
A cyclosporine 0.05% ophthalmic emulsion (Restasis - Allergan) has been approved by the FDA for use in patients with dry eye disease (keratoconjunctivitis sicca). This review begins with a discussion of the causes of dry eye disease and includes sections on the pharmacology, adverse effects and clinical trial results for ophthalmic cyclosporine. Cost information and recommendations for administering the drug are also presented. The review concludes with an overall assessment of the drug's efficacy, safety and cost.
Med Lett Drugs Ther. 2003 May 26;45(1157):42-3 |  Show IntroductionHide Introduction

In Brief: IV Artesunate for Severe Malaria

   
The Medical Letter on Drugs and Therapeutics • May 19, 2008  (Issue 1286)
travelers, and about 5% of these have severe disease. 4 Artesunate is generally given over 3 days in 2.4 ...
The drug of choice for patients who require parenteral treatment for malaria is IV artesunate, which is available now from the CDC Malaria Branch (M-F, 8 AM-4:30 PM eastern time, 770-488-7788 or, after hours, 770-488-7100). Artesunate appears to be more effective than quinine1 and safer than quinidine, the other parenteral alternatives in the US. The CDC has supplies of artesunate in Atlanta and in 8 quarantine stations in major airports around the US. It will release the drug for appropriate patients (severe disease or unable to take oral drugs) if it can be supplied as quickly as quinidine,...
Med Lett Drugs Ther. 2008 May 19;50(1286):37 |  Show IntroductionHide Introduction

Lurasidone (Latuda) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011  (Issue 1358)
maintenance dosage for schizophrenia in adult patients 1. Cost for 30 days’ treatment with the lowest usual ...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.
Med Lett Drugs Ther. 2011 Feb 21;53(1358):13-4 |  Show IntroductionHide Introduction

Potassium Iodide for Thyroid Protection in a Nuclear Accident

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2011  (Issue 1361)
have a concentration of 130 mg/8 teaspoons, can be kept in the refrigerator for up to 7 days. AVAILABILITY ...
Even though it is unlikely that people living in the US will be at risk of significant radiation exposure from the nuclear accident in Japan, some readers have suggested a review of the use of potassium iodide (KI) in such circumstances. Potassium iodide taken orally before or at the time of exposure can limit or prevent uptake of radioactive iodine by the thyroid gland.
Med Lett Drugs Ther. 2011 Apr 4;53(1361):25-6 |  Show IntroductionHide Introduction